Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments [Reuters]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: Reuters
May 6 (Reuters) - Vertex Pharmaceuticals beat Wall Street estimates for first-quarter profit on Monday, driven by robust uptake for its cystic fibrosis treatments. Cystic fibrosis (CF) - an inherited disorder that causes severe damage to the lungs, digestive system and other organs - affects an estimated 105,000 people across 94 countries, according to data from U.S.-based CF Foundation. Sales from Vertex's top-selling CF drug Trikafta, also sold as Kaftrio in some markets, rose more than 18% from a year earlier to $2.48 billion in the quarter, beating analysts' expectations of $2.38 billion. Vertex reported adjusted earnings per share of $4.76 on revenue of $2.69 billion, topping market estimates $4.06 on revenue of $2.58 billion, according to LSEG data, for the quarter ended March 31. The drugmaker reiterated its annual revenue forecast of between $10.55 billion and $10.75 billion. The Boston, Massachusetts-based company has been making efforts to expand its product pipel
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So. [Yahoo! Finance]Yahoo! Finance
- Jennifer Schneider Elected to Vertex Board of Directors [Yahoo! Finance]Yahoo! Finance
- Jennifer Schneider Elected to Vertex Board of DirectorsBusiness Wire
- Circular RNA: Vaccines, therapeutics and biomarkers could be revolutionised [Yahoo! Finance]Yahoo! Finance
- Vertex Is Writing A New Playbook For Pharma R&D. And It's Working. [Forbes]Forbes
VRTX
Earnings
- 5/6/24 - Beat
VRTX
Sec Filings
- 5/17/24 - Form 4
- 5/17/24 - Form 4
- 5/17/24 - Form 4
- VRTX's page on the SEC website